Highlights Morphic Holding, Inc.

Equities

MORF

US61775R1059

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
30.23 ^USD	+6.59%		+3.07%	+4.67%

04-25	Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-19	Morphic Holding Names Simon Cooper as Chief Medical Officer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls	02-22	MT
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
North American Morning Briefing : Stock Futures -2-	02-21	DJ
Morphic Ethical Equities Fund Buys Back Shares	12-27	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Morphic Holding, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Morphic Reports Positive Topline Results of the Emerald-1 Uc Main Cohort	23-04-25	CI
Morphic 2022 Loss Narrows, Revenue Rises	23-02-23	MT
MORPHIC HOLDING, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-02-23	AQ
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Morphic Starts Phase 2b Trial of MORF-057 in Ulcerative Colitis Patients	22-11-22	MT
Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis	22-11-22	CI
Morphic Holding Q3 Loss Widens as Revenue Declines	22-11-02	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022	22-10-25	CI
Morphic Completes Enrollment in Ulcerative Colitis Trial Early	22-10-24	MT
Morphic Therapeutic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections	22-10-24	CI
Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022	22-10-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Morphic Holding, Inc.

Equities

MORF

US61775R1059

Highlights

Filters